KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Inventory (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Inventory for 17 consecutive years, with $740.7 million as the latest value for Q4 2025.

  • Quarterly Inventory fell 2.54% to $740.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $740.7 million through Dec 2025, down 2.54% year-over-year, with the annual reading at $740.7 million for FY2025, 2.54% down from the prior year.
  • Inventory for Q4 2025 was $740.7 million at Bio-Rad Laboratories, down from $783.2 million in the prior quarter.
  • The five-year high for Inventory was $804.3 million in Q3 2024, with the low at $572.2 million in Q4 2021.
  • Average Inventory over 5 years is $719.2 million, with a median of $756.5 million recorded in 2023.
  • The sharpest move saw Inventory fell 8.04% in 2021, then increased 25.7% in 2022.
  • Over 5 years, Inventory stood at $572.2 million in 2021, then rose by 25.7% to $719.3 million in 2022, then rose by 8.51% to $780.5 million in 2023, then fell by 2.63% to $760.0 million in 2024, then fell by 2.54% to $740.7 million in 2025.
  • According to Business Quant data, Inventory over the past three periods came in at $740.7 million, $783.2 million, and $798.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.